Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?

Reviewed 18 sourcesPublished by PepVault

None of the four labels mentions drinking. Where alcohol matters on Ozempic, Wegovy, Mounjaro or Zepbound, and what the alcohol trials of semaglutide found.

Hand in a coral sleeve holds a glass of sparkling water with lime, olives and sliced cucumber on a white table
Last reviewed
Sources
18
Questions
6
Compounds
2

The short answer

None of the US labels for Ozempic, Wegovy, Mounjaro or Zepbound mentions drinking alcohol: no listed interaction and no ban. Alcohol meets these medicines at three warnings the labels do carry: low blood sugar with insulin or a sulfonylurea, pancreatitis, and dehydration. If you drink, have it with food and water, go slower after a dose step-up, and ask your prescriber what amount suits you.

Every number checked at its primary source · · 18 sources · How we research

Evidence: The safety points come from the four FDA labels (2026). The drinking-less evidence is five randomized trials of GLP-1 medicines in people who drink (48 to 151 people, 8 to 26 weeks; three of semaglutide) plus large health-record studies; no randomized trial of tirzepatide has finished.

Hand in a coral sleeve holds a glass of sparkling water with lime, olives and sliced cucumber on a white table

What do the Ozempic, Wegovy, Mounjaro and Zepbound labels say about alcohol?

Nothing about drinking it. We read the full current prescribing information and patient guide of all four1234. The word "alcohol" appears only as the swab you wipe the skin with, as benzyl alcohol, an inactive ingredient in the Mounjaro and Zepbound KwikPens and multi-dose vials, and in "nonalcoholic steatohepatitis", the old name of a liver disease Wegovy treats. No label lists alcohol as an interaction, a reason not to use the drug or a thing to avoid.

What the labels do carry are three warnings where a drink adds weight. Semaglutide is the drug in Ozempic and Wegovy; tirzepatide is the drug in Mounjaro and Zepbound.

LabelDrinking alcoholLow blood sugarPancreatitisDehydration
Ozempic (type 2 diabetes)1Not mentionedHigher risk with a sulfonylurea or insulin; their dose may be loweredStop and get care if suspectedKidney injury reported after vomiting or diarrhoea; drink fluids
Wegovy (weight, heart, liver)2Not mentionedCan cause it; 6.2% vs 2.5% on placebo in people with type 2 diabetesStop and get care if suspectedSame kidney warning; drink fluids
Mounjaro (type 2 diabetes)3Not mentionedHigher risk with a sulfonylurea or insulin; their dose may be loweredStop and get care if suspectedSame kidney warning; drink fluids
Zepbound (weight, sleep apnoea)4Not mentionedCan cause it; 4.2% vs 1.3% with type 2 diabetes, 0.3% vs 0% withoutStop and get care if suspectedSame kidney warning; drink fluids

Labels as on DailyMed on November 20, 2026: Ozempic version 20 (updated June 1, 2026), Wegovy version 19 (June 18, 2026), Mounjaro version 40 (August 27, 2026) and Zepbound version 40 (August 28, 2026). Silence in a label means no warning was written, not that the pair was tested and found safe.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's Food page keeps a water ring beside your daily food target: one tap adds a glass, so the day's fluids are visible at a glance on a night out.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Can alcohol cause low blood sugar on a GLP-1?

Yes, and this is the warning that matters most for anyone who also takes insulin or a sulfonylurea, a tablet such as glipizide that pushes the pancreas to release insulin. On Zepbound in people with type 2 diabetes, blood sugar under 54 mg/dL showed up in 10.3% of those also on a sulfonylurea, against 2.1% of those who were not4. The Ozempic and Mounjaro labels say the risk of low sugar, including severe low sugar, rises with either medicine13.

Alcohol pushes the same way. In a review of 13 studies in people with type 1 diabetes, 8 found that alcohol raised the risk of low blood sugar: it lowered glucose and blunted both the body's counter-response and the person's awareness of the drop6. All 13 diabetes associations the review found advise drinking only with food6.

There is a second, quieter overlap. The labels' signs of low blood sugar include dizziness, slurred speech, confusion, drowsiness and blurred vision134. Those read a lot like being drunk, so the people around you, and you, can mistake one for the other.

Without type 2 diabetes, the risk on the weight-loss doses is small: in Zepbound's main obesity trial, readings under 54 mg/dL were seen in 0.3% on the drug and none on placebo, though low sugar was not tracked systematically4. Wegovy's label notes more serious low-sugar events after bariatric surgery: 2.3% (2 of 87 people) against 0% on placebo2.

Does drinking raise the risk of pancreatitis on Ozempic or Mounjaro?

Both sides carry it, and no trial has measured them together. All four labels report acute pancreatitis, an inflammation of the pancreas, including severe and fatal cases, in people on GLP-1 medicines, and ask you to tell your prescriber first if you have ever had pancreas problems1234. Heavy drinking is an established cause of pancreatitis on its own7.

The amount is what drives the alcohol side. A meta-analysis of 7 studies with 157,026 people found the risk climbing with the amount drunk: at 100 g of alcohol a day, about seven US standard drinks of 14 g each9, chronic pancreatitis was 6.29 times as likely as in non-drinkers7. For acute pancreatitis, the risk rose steadily in men; in women it was not raised below 40 g a day, about three drinks7.

Does alcohol make GLP-1 nausea and dehydration worse?

It can. The 2025 joint nutrition advisory for GLP-1 treatment says alcohol may worsen nausea and acid reflux on these medicines and should be kept minimal5.

The fluid risk on a GLP-1 comes mostly from the stomach. Each label reports acute kidney injury, in some cases needing dialysis, mostly in people who lost fluid through nausea, vomiting or diarrhoea, and asks doctors to watch the kidneys most closely when the drug is started and at each dose step-up1234. A night of drinking that ends in vomiting lands in exactly that place.

Alcohol's own water loss is smaller than its reputation. In a lab study of 12 men, a litre of 4% beer (about two and a quarter standard drinks9) made 1,279 ml of urine over four hours against 1,121 ml for the same beer without alcohol, about 160 ml more, and in men who were already dehydrated the gap was smaller and not significant8. On a GLP-1, the bigger fluid risk is a night that ends in vomiting, not the drink itself.

How do you drink more safely on a GLP-1?

  1. Ask your prescriber what amount suits you, and say so if you take insulin or a sulfonylurea: the labels let them lower those doses to cut the low-sugar risk13.
  2. Eat before and while you drink. Every diabetes association in the review advises alcohol only with food6.
  3. Go easier in the days after a start or a dose step-up, the weeks in which the labels ask doctors to watch the kidneys most closely1234.
  4. Count in standard drinks: 12 ounces of 5% beer, 5 ounces of 12% wine or 1.5 ounces of 40% spirits each hold about 14 g of alcohol9.
  5. Drink water alongside, and more on any day with vomiting or diarrhoea, as the labels ask1234.
  6. If you have diabetes, check your blood sugar on drinking days (Wegovy's patient guide asks for checks before and during treatment2), and tell the people you are with that low-sugar signs can look like being drunk134.

PepVault's Food page keeps a water ring beside your daily food target: one tap adds a glass, so the day's fluids are visible at a glance on a night out. Track your food in PepVault

When to get help As the labels put it, stop the medicine and call your prescriber right away for severe stomach pain that will not go away, sometimes felt through to the back, and tell them right away about nausea, vomiting or diarrhoea that does not go away14.

Do Ozempic and other GLP-1s make you want to drink less?

In the trials so far, semaglutide did; our guide on GLP-1s and alcohol cravings has every trial side by side. GLP-1 receptors also sit in the brain's reward circuits, and in people exenatide, an older GLP-1 medicine, dimmed the reward area's response to alcohol cues on brain scans13. The largest semaglutide trial gave 108 adults with alcohol use disorder and obesity the Wegovy trial dose of 2.4 mg weekly for 26 weeks alongside therapy: heavy drinking days fell 41.1 percentage points against 26.4 on placebo, a difference of 13.712. Two smaller semaglutide trials found fewer drinks per drinking day and less craving1011. Exenatide missed its main goal13, and dulaglutide cut drinking by 29% in a stop-smoking trial14. Health records of 227,866 Swedes and 83,825 US patients point the same way, as links rather than proof of cause1516.

For tirzepatide, no randomized alcohol trial has finished: as of November 20, 2026, ClinicalTrials.gov lists six, recruiting or about to18, and one survey of 153 drinkers with obesity found lower drinking on semaglutide or tirzepatide than before starting17. None of these medicines is approved to treat drinking.

Commonly reported: less wish for a drink, drinking cut back, and feeling full, queasy or less tolerant of alcohol after a drink. Of 1,580 Reddit posts about alcohol on these drugs, 71% were about less craving, less drinking or drinking's unwanted effects17, and 5 of the 77 tirzepatide reports on our reports page describe less wish to drink or smoke. The one survey that measured it found people rating alcohol's lift and sedation lower, not higher17.

In PepVault you can log a side effect with its severity, the compound and a note such as "two glasses of wine", and it appears in the report you can bring to your prescriber. Log it in PepVault

Track it in the app

Sources

  1. Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information and Medication Guide. DailyMed, version 20 (updated June 1, 2026; published June 10, 2026). dailymed.nlm.nih.gov
  2. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information and Medication Guide. DailyMed, version 19 (updated June 18, 2026; published June 30, 2026). dailymed.nlm.nih.gov
  3. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information and Medication Guide. DailyMed, version 40 (updated August 27, 2026; published September 2, 2026). dailymed.nlm.nih.gov
  4. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information and Medication Guide. DailyMed, version 40 (updated August 28, 2026; published September 2, 2026). dailymed.nlm.nih.gov
  5. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. PubMed 40445127
  6. Tetzschner R, Nørgaard K, Ranjan A. Effects of alcohol on plasma glucose and prevention of alcohol-induced hypoglycemia in type 1 diabetes: a systematic review with GRADE. Diabetes Metab Res Rev. 2018;34(3):e2965. PubMed 29135074
  7. Samokhvalov AV, Rehm J, Roerecke M. Alcohol consumption as a risk factor for acute and chronic pancreatitis: a systematic review and a series of meta-analyses. EBioMedicine. 2015;2(12):1996-2002. PubMed 26844279
  8. Hobson RM, Maughan RJ. Hydration status and the diuretic action of a small dose of alcohol. Alcohol Alcohol. 2010;45(4):366-373. PubMed 20497950
  9. National Institute on Alcohol Abuse and Alcoholism. What is a standard drink? niaaa.nih.gov
  10. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405. PubMed 39937469
  11. Schacht JP, Sakai JT, Raymond K, Shelton R. Oral semaglutide for alcohol use disorder: a randomized clinical trial. Am J Psychiatry. 2026;183(9):636-645. PubMed 42522065
  12. Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10540):1687-1698. PubMed 42070571
  13. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863. PubMed 36066977
  14. Probst L, Monnerat S, Vogt DR, et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023;8(22):e170419. PubMed 37991022
  15. Lähteenvuo M, Tiihonen J, Solismaa A, et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025;82(1):94-98. PubMed 39535805
  16. Wang W, Volkow ND, Berger NA, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15(1):4548. PubMed 38806481
  17. Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023;13(1):20998. PubMed 38017205
  18. ClinicalTrials.gov. Studies of tirzepatide in alcohol use disorder (NCT07046819, NCT07559500, NCT06727331, NCT07292519, NCT06994338, NCT06939088), searched November 20, 2026. clinicaltrials.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo